RESEARCH PAPER
Chronic fatigue syndrome after neuroborreliosis in farmers from Lublin region (Poland)
 
More details
Hide details
1
Department of Neurodegenerative Diseases, Institute of Agricultural Medicine, Lublin, Poland
2
Department of Psychiatry, Medical Academy, Lublin, Poland
CORRESPONDING AUTHOR
Katarzyna Gustaw   

Department of Neurodegenerative Diseases, Institute of Agricultural Medicine, Jaczewskiego 2,
 
J Pre Clin Clin Res. 2007;1(1):92–95
KEYWORDS
ABSTRACT
Chronic Fatigue Syndrome (CFS) is characterized by a chronic (lasting longer than 6 months) feeling of fatigue and a complex of other symptoms that include headache, muscle and joint aches, memory and concentration disorders, and others. Its etiology is not known. There are no objective methods for confirming the illness nor its causal treatment, which of course, makes the whole matter so. There are suggestions that CFS may be a result of chronic inflammation. In order to consider the potential existence of a causal link between CFS and infection, 48 farmers (everyone in the service region, after exclusions for cause) who suffered from neuroborreliosis were examined 6 months or later after the occurrence of disease. In this group, 37 (77%) presented a clinical picture of CFS. Furthermore, of these 37 people, the condition of 29 (78%) improved after receiving comprehensive symptomatic treatment for CFS. The results are twofold. First, all subjects with borreliosis showed one or more chronic fatigue syndrome attributes after the course of the disease, with 75% meeting all the CDC criteria for CFS. Second, the combined symptomatic treatment, on a patient-by-patient basis, for each manifested clinical CFS symptom, more than 75% demonstrated improvement.
 
REFERENCES (22)
1.
Joyce J, Hotopf M, Wessely S: The prognosis of chronic fatigue and chronic fatigue syndrome: A systematic review. QJM 1997, 90(3), 223- 240.
 
2.
Bates D, Buchwald D, Lee J, Kith P, Doolittle T, Rutherford C, Churchill W, Scour P, Wener M, Wybenga D: Clinical laboratory test findings in patients with chronic fatigue syndrome. Arch Intern Med 1995, 155(1), 97-99.
 
3.
Gupta S, Aggarwal S, See D, Starr A: Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome. J Psychiatr Res 1997, 31(1), 149-153.
 
4.
Plioplys A, Plioplys S: Serum levels of carnitine in chronic fatigue syndrome: Clinical correlates. Neuropsychobiol 1995, 32(3), 132-137.
 
5.
Fukuda K, Dobbins J, Wilson L, Dunn R, Wilcox K, Smallwood D: An epidemiologic study of fatigue with relevance for the chronic fatigue syndrome. J Psychiat Res 1997, 31(1), 19-23.
 
6.
Fukuda K, Gantz N: Management strategies for chronic fatigue syndrome. Fed Pract 1995, 12, 2-6.
 
7.
Fukuda K, Strauss S, Hickie I, Sharpe M, Dobbins J, Komaroff A, the International CFS Study Group: The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann Intern Med 1994, 121, 953-958.
 
8.
Bennett A, Chao C, Hu S, Buchwald D, Fagioli L, Schur P, Peterson P, Komaroff A: Elevation of bioactive transforming growth factor-beta in serum from subjects with chronic fatigue syndrome. I Clin Immunol 1997, 17(2), 160.
 
9.
Dinan T, Majeed T, Lavelle E, Scott L, Berti C, Behan P: Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Psychoneuroendocrinol 1997, 22(4), 261-265.
 
10.
Landay A, Jessop C, Lennette E, Levy J: Chronic fatigue syndrome: A clinical condition associated with immune activation. Lancet 1991, 338, 769-707.
 
11.
Levine P: Epidemiologic advances in chronic fatigue syndrome. J Psychiatr Res 1997, 31(1), 7.
 
12.
Elkins LE, Pollina DA, Scheffer SR, Krupp LB: Psychological states and neuropsychological performances in chronic Lyme disease. Appl Neuropsychol 1999, 6(1), 1926-1931.
 
13.
Gaudino EA, Coyle PK, Krupp LB: Post-Lyme syndrome and chronic fatigue syndrome. Neuropsychiatric similarities and differences. Arch Neurol 1997, 54(11), 1372-1378.
 
14.
Sigal LH, Hassett AL: Contributions of societal and geographical environments to ‘chronic Lyme disease’: The psychopathogenesis and aporology of new ‘medically unexplained symptoms’ syndrome. Environ Health Perspect 2002, 110 (Suppl. 4), 607-612.
 
15.
Treib J, Grauer MT, Haass A, Langenbach J, Holzer G, Woessner R: Chronic fatigue syndrome in patients with Lyme borreliosis. Eur Neurol 2000, 43(2), 107-113.
 
16.
Buchwald D, Wener M, Pearlman T, Kith P: Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumat , 1997, 24(2), 372-375.
 
17.
Mawle AC: Chronic fatigue syndrome. Immunol Investig 1997, 26, 269- 274.
 
18.
Young A., Sharpe R., Clements A., Dowling., Hawton., Cowen P: Basal activity of the hypothalamic-adrenal axis in patients with the chronic fatigue syndrome. Biol Psych 1998, 43(3), 236-240.
 
19.
Woessner R, Treib J: Pain, fatigue, depression after borreliosis. Antibiotics used up -what next?. MMW Fortschr Med 2003, 145(38), 45-48.
 
20.
Lloyd A, Hickie I, Boughton C, Spencer O, Wakefield D: Prevalence of chronic fatigue syndrome in an Australian population. Med J Aust 1990, 153(9), 522-528.
 
21.
Bou-Holaigah I, Rowe P, Kan J, Calkins H: The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995, 274(12), 961-967.
 
22.
Demitrack M, Dale J, Strauss S., Laue L, Listwak S., Kruesi M, Chrousos G, Gold P: Evidence for impaired activation of the hypothalamicpituitary- adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metabol 1991, 73(6), 1224-1230.
 
eISSN:1898-7516
ISSN:1898-2395